About CellTC
Built by scientists. Trusted by institutions.
CellTC was founded by cell therapy researchers who recognized a critical gap: programs failing not from lack of science, but from lack of strategic clarity. We bridge that gap.
Our Mission
Accelerate the translation of cell therapy science into approved treatments.
We believe the most important breakthroughs in medicine are still ahead — and that rigorous, science-first advisory is what separates programs that reach patients from those that stall in development.
Leadership
The consulting team
Dr. Elena Vasquez
Founder & Principal Consultant
PhD Immunology, MD Oncology
Former Director of Clinical Development at a leading CAR-T biotech. Led three IND submissions and two Phase II trials across hematologic malignancies.
Dr. Marcus Chen
Senior Advisor, CMC & Manufacturing
PhD Bioprocess Engineering
15 years in cell therapy manufacturing scale-up. Former VP of Process Development at a global CDMO, overseeing autologous and allogeneic platform transitions.
Dr. Sarah Okonkwo
Senior Advisor, Regulatory Affairs
PhD Molecular Biology, RAC
Former Senior Reviewer at the FDA's Office of Tissues and Advanced Therapies. Deep expertise in RMAT designation, BLA submissions, and agency meeting strategy.
Our Philosophy
No templates. No generalists.
Evidence before strategy
Every recommendation is grounded in a rigorous review of your scientific data, competitive landscape, and regulatory precedent. We do not apply generic frameworks.
Regulatory precision
We write to the agency's expectations — not around them. Our regulatory documents are built to withstand scrutiny, not to check a box.
Long-term partnership
We engage as embedded advisors, not transactional consultants. Our success is measured by your program's advancement, not by deliverable count.
Work with our team.
Schedule a confidential consultation to discuss your program's development challenges.
For qualified medical and research institutions only.